Retatrutide Bio

T-03

Study-dose explorer

Pick a trial and a protocol arm; the explorer shows what that arm actually received and what was measured, with the trial stage pinned to every output. Educational display of published arm-level data; it computes nothing about any person and accepts no personal inputs.

Pick a trial and a protocol arm; the explorer shows what that arm actually received and what was measured, with the trial stage pinned to every output. Educational display of published arm-level data; it computes nothing about any person and accepts no personal inputs.

Published records (17 of 17)

TrialArmMaintenance mgWeight change 48wk %Publication
Phase 2 obesity (NCT04881760)Placebo0-2.1NEJM 2023
Phase 2 obesity (NCT04881760)1 mg1-8.7NEJM 2023
Phase 2 obesity (NCT04881760)4 mg (combined)4-17.1NEJM 2023
Phase 2 obesity (NCT04881760)8 mg (combined)8-22.8NEJM 2023
Phase 2 obesity (NCT04881760)12 mg12-24.2NEJM 2023
Phase 2 type 2 diabetes (NCT04867785)Placebo0not statedLancet 2023
Phase 2 type 2 diabetes (NCT04867785)Dulaglutide 1.5 mg (active comparator)not statednot statedLancet 2023
Phase 2 type 2 diabetes (NCT04867785)12 mg (escalation)12not statedLancet 2023
TRANSCEND-T2D-1, phase 3 (NCT06354660)Placebo0not statedLancet 2026
TRANSCEND-T2D-1, phase 3 (NCT06354660)4 mg4not statedLancet 2026
TRANSCEND-T2D-1, phase 3 (NCT06354660)9 mg9not statedLancet 2026
TRANSCEND-T2D-1, phase 3 (NCT06354660)12 mg12not statedLancet 2026
MASLD substudy (NCT04881760)Placebo0not statedNat Med 2024
MASLD substudy (NCT04881760)1 mg1not statedNat Med 2024
MASLD substudy (NCT04881760)4 mg4not statedNat Med 2024
MASLD substudy (NCT04881760)8 mg8not statedNat Med 2024
MASLD substudy (NCT04881760)12 mg12not statedNat Med 2024

Every row restates a published record; sources resolve on the sourced monograph. Species is part of the data: this table never scales an animal dose into a human figure.

Tools: educational calculators and references only.

Compare available GLP-1 plans